Creating a New Class of Drugs to Address Incurable Autoimmune Diseases
Company is active
Event Year: 2021
Company is active
Event Year: 2021
Entelexo Biotherapeutics is pioneering a new era in the treatment of immune-mediated diseases. Focusing on conditions like psoriasis, the company is developing innovative therapies leveraging engineered exosome technology. Their approach aims to create more effective and targeted treatments for autoimmune disorders, offering hope for patients with currently incurable conditions. Entelexo's research and development efforts are centered on harnessing the power of exosomes to deliver therapeutic payloads directly to affected cells, potentially minimizing side effects and maximizing efficacy.
Entelexo Biotherapeutics is pioneering a new era in the treatment of immune-mediated diseases. Focusing on conditions like psoriasis, the company is developing innovative therapies leveraging engineered exosome technology. Their approach aims to create more effective and targeted treatments for autoimmune disorders, offering hope for patients with currently incurable conditions. Entelexo's research and development efforts are centered on harnessing the power of exosomes to deliver therapeutic payloads directly to affected cells, potentially minimizing side effects and maximizing efficacy.
Total Raised: Unknown (Y Combinator backed)
Last Round: Winter 2021
Total Raised: Unknown (Y Combinator backed)
Last Round: Winter 2021
Healthcare
Healthcare
Healthcare -> Therapeutics
Healthcare -> Therapeutics
Team size: 3
Hiring: No
Team size: 3
Hiring: No
